Fig. 10
From: Feasibility of machine learning–based modeling and prediction to assess osteosarcoma outcomes
Immunotherapeutic response prediction by TIDE. (A) Patients were classified as potential responders or non-responders to immunotherapy based on their TIDE values in the merged cohort. (B) Differences in Dysfunction scores between high- and low-risk score groups (P < 0.001). (C) Percent weight of clinical response to immunotherapeutic in high- and low-risk score groups. (D) Differences in TIDE scores between high- and low-risk score groups (P = 0.02).
